These publications have been authored or co-authored by DRIVE-AB participants while actively contributing to the project.
Article in Clinical Microbiology and Infection by a number of DRIVE-AB partners. 1 August 2017.
Article in Plos One by DRIVE-AB Work Package 1B partners. 20 July 2017.
Article in Clinical Microbiology and Infection by DRIVE-AB partner Ursula Theuretzbacher. 23 June 2017.
- Linking sustainable use policies to novel economic incentives to stimulate antibiotic research and development
Article in Infectious Disease Reports. Co-authored by DRIVE-AB partners Ursula Theuretzbacher, Christine Årdal, and Stephan Harbarth. March 2017.
DRIVE-AB partners and data contributed to the World Health Organization’s Priority Pathogen List. February 2017.
Article in The New York Times. Co-authored by DRIVE-AB partner Kevin Outterson. 18 January 2017.
- EpideMiology and control measures of outBreaks due to Antibiotic-Resistant organisms in EurOpe (EMBARGO): a systematic review protocol
British Medical Journal article written by Work Package 1B participants. 1 January 2017.
An article published in PLOS Medicine. Co-authored by DRIVE-AB academic co-coordinator Stephan Harbarth. 29 November, 2016.
A report on an interview with DRIVE-AB participant Ursula Theuretzbacher, published by European Hospital in Healthcare in Europe. 27 October, 2016.
An article published in Nature in advance of the United Nations General Assembly. Co-authored by DRIVE-AB academic co-coordinator Stephan Harbarth and partners Ramanan Laxminarayan and Anthony So. 7 September, 2016.
- Exploring the obstacles to implementing economic mechanisms to stimulate antibiotic research and development: A multi-actor and system-level analysis
An article published in the American Journal of Law & Medicine, written by DRIVE-AB Work Package 2 partners Enrico Baraldi, Francesco Ciabuschi, Chantal Morel and Alexandra Waluszewski as well as former DRIVE-AB partner Ross Leach. May 2016.
A commentary published in The Lancet in advance of the United Nations General Assembly in September, which will address antimicrobial resistance. Co-authored by DRIVE-AB partners Ramanan Laxminarayan, Otto Cars, David Heymann and John-Arne Røttingen. 16 July, 2016.
- Poster: Survey on the activities of the World Health Organization (WHO) against antimicrobial resistance (AMR)
A poster presenting the results of the World Health Organization survey on activities to combat antimicrobial resistance. Co-authored by DRIVE-AB Coordinator Stephan Harbarth and Team Leader John-Arne Røttingen.
- Delinking investment in antibiotic research and development from sales revenues: The challenges of transforming a promising idea into reality
An essay on the challenges of implementing models and policies to delink rewards from sales volume of antibiotics, co-authored by DRIVE-AB partners Kevin Outterson, Charles Clift, Anthony So, Chantal Morel and John-Arne Røttingen. Published in PLOS Medicine. 14 June, 2016.
A development dialogue paper published by the Dag Hammarskjöld Foundation, co-authored by DRIVE-AB partners Dušan Jasovský, Anna Zorzet and Otto Cars. April 2016.
- A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics
A systematic review of incentive strategies for antibiotic R&D, co-authored by DRIVE-AB participant Elias Mossialos and mentioning the consortium’s work on developing new reward models. February 2016
World Report in The Lancet, with input from two DRIVE-AB participants, John-Arne Røttingen and Kevin Outterson, mentioning DRIVE-AB in the context of global action to stimulate antibiotics innovation. 7 May, 2016.
This article,by DRIVE-AB participant Ramanan Laxminarayan, discusses emerging threats, including antimicrobial resistance, to global public health as a result of trans-boundary commons. Published in the Oxford Review of Economic Policy in spring 2016.
This article, co-authored by a number of DRIVE-AB participants, discusses the importance of a coordinated, global, multi-sector response to address access, conservation and innovation of antimicrobials. Published in the The Lancet on 16 January 2016.
This article, co-written by one DRIVE-AB participant John Rex, discusses current alternatives to antibiotics, which were defined as non-compound approaches (products other than classic antibacterial agents) that target bacteria or any approaches that target the host. January 2016.
Article published in Clinical Microbiology and Infection co-authored by DRIVE-AB partners Elizabeth Temkin and Yehuda Carmeli. Published on 17 December 2015.
This Innovative Medicines Initiative fact sheet features DRIVE-AB in a segment on how IMI projects are making progress in the field of antimicrobial resistance.
DRIVE-AB coordinator Stephan Harbarth and other participants Herman Goossens and Ramanan Laxminarayan have contributed to this article on the global nature of the antimicrobial resistance threat and the need for a ‘One Health’ approach. Published in Antimicrobial Resistance & Infection Control on 18 November 2015.
In celebration of Global Antibiotic Awareness Day, 18 November 2015, The Lancet, in collaboration with Imperial College London and the Norwegian Institute of Public Health, has published a series on antimicrobial resistance, with contributions from some DRIVE-AB members. To read a more thorough description of the series, please click here.
One such article in the series was co-authored by DRIVE-AB participants Ramanan Laxminarayan and John-Arne Røttingen: Access to effective antimicrobials: a worldwide challenge.
- Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study
Co-authored by DRIVE-AB participant Ramanan Laxminarayan, this The Lancet Infectious Diseases article was funded by DRIVE-AB. 16th October 2015.
DRIVE-AB Work Package 3B (Communications) co-lead Ursula Theuretzbacher authors this article, published in October 2015 in European Biotechnology: Life sciences and industry magazine, Volume 14. The article focuses on the need for new economic incentives for antibiotic research and development, and how the Innovative Medicines Initiative project DRIVE-AB will aim to address this problem.
DRIVE-AB participants Charles Clift, Kevin Outterson, and John-Arne Røttingen have released a report on 9 October 2015 with Chatham House that aims to inform the ongoing discussions and processes on developing a new business model for antibiotics.
DRIVE-AB Work Package 1C (Antibiotic Valuation) co-lead Ramanan Laxminarayan, Center for Disease Dynamics, Economics and Policy, co-authored an article on the antimicrobial resistance and responsibilities to tackle the problem on both global and local scales. September 2015.
A supplement to The Journal of Law, Medicine and Ethics (JLME) Volume 43:2, which focuses on the need to establish an international agreement for antibiotic policy, and what areas such an agreement should address. The supplement is co-guest edited by DRIVE-AB participants Kevin Outterson and Steven Hoffman, with articles written by further DRIVE-AB participants.
ReAct Group has published a comprehensive summary of the series of articles in its news release on 3 August 2015.
DRIVE-AB participant Otto Cars co-authors this article in the International Journal of Antimicrobial Agents discussing the ethical issues associated with antibiotic resistance. The article suggests that current policy descussions should take ethical conflicts into account when discussing the challenges to and recommendations for curbing the threat of antibiotic resistance. June 2015.
- Commentaries on the UK AMR Review Report: Securing new drugs for future generations: The pipeline of antibiotics (May 2015)
Three DRIVE-AB participants comment on the UK Review on Antimicrobial Resistance report that was released in May, 2015 on securing the antibiotics pipeline.
An article published by PLOS Medicine on the need for a sustainably financed global R&D fund and mechanism that promotes coordination, collaboration, and utilization of new and innovative incentives for antimicrobial resistance, emerging infectious diseases, and neglected diseases. May 2015.
DRIVE-AB external partner Keven Outterson is interviewed by Peter Doshi, associate editor of the BMJ, for the first installment of a series on antibiotics. This article explores the results of the 2012 legislation to fast-track the approval of certain antibiotics, the Generating Antibiotic Incentives Now Act (GAIN). 25th March, 2015.
DRIVE-AB Work Package 3B academic leader Ursula Theuretzbacher gives an overview of the good and the bad news relating to antibiotic discovery over the last year. March 2015.
Research report from Chatham House and Big Innovation Centre offering innovative models and ideas that address many of the critical questions about the misalignment between the need for new antibiotics and the incentives for their development. Co-authored by DRIVE-AB partner Kevin Outterson. February 2015.
Appendix can be viewed here: Business Model Options for Antibiotics APPENDICES
Op-ed piece by John-Arne RØttingen published in the Norwegian newspaper Dagens Naeringsliv (‘Business Today’), February 2015.
English translation also available here: The solution to the antibiotics riddle
The Journal of Antimicrobial Chemotherapy has published a leading article about DRIVE-AB. February 2015.
Steven J Hoffman, Kevin Outterson, John-Arne Røttingen, Otto Cars, Charles Clift, Zain Rizvi, Fiona Rotberg, Göran Tomson & Anna Zorzet, Bulletin of the World Health Organization,93(2), 65-132, February 2015.
Kevin Outterson, John H. Powers, Gregory W. Daniel, and Mark B. McClellan, Health Affairs 34(2), 277-285, February 2015.
Carl Nathan, M.D., and Otto Cars, New England Journal of Medicine, October 2014.
- UK and European Union public and charitable funding from 2008 to 2013 for bacteriology and antibiotic research in the UK: an observational study
Eilis C ;